Literatuurlijst Farmacotherapie onderhoudsbehandeling

• Adab, N., Kini, U., Vinten, J., Ayres, J., Baker, G., Clayton-Smith, J., e.a. (2004a). The longer term outcome of children born to mothers with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry, 75, 1575-1583.
• Adab, N., Tudur, S.C., Vinten, J., Williamson, P., & Winterbottom, J. (2004b). Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database of Systematic Reviews 2004(3), Article CD004848. The Cochrane Library Database.
• Ahlfors, U.G., Baastrup, P.C., Dencker, S.J., Elgen, K., Lingjaerde, O., Pedersen, V. e.a. (1981). Flupenthixol decanoate in recurrent manic-depressive illness: A comparison with lithium. Acta Psychiatrica Scandinavica, 64, 226-237.
• Aigner, M. (2010). Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: A randomized, double-blind, placebosubstitution study. Journal fur Neurologie, Neurochirurgie und Psychiatrie, 11, 86-87.
• Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C., Infante, M.C., e.a. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156, 1686-1696.
• Altamura, A., Russo, M., Vismara, S., & Mundo, E. (2004). Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder. Journal of Clinical Psychopharmacology, 24, 454-456.
• Altamura, A.C., Salvadori, D., Madaro, D., Santini, A., & Mundo, E. (2003). Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. Journal of Affective Disorders, 76, 267-271.
• Amsterdam, J.D., & Shults, J. (2005). Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. International Clinical Psychopharmacology, 20, 257-264.
• Amsterdam, J.D., & Shults, J. (2010). Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar ii disorder: a randomized, doubleblind, placebo-substitution study. American Journal of Psychiatry, 167, 792-800.
• Amsterdam, J.D., Luo, L., & Shults, J. (2013). Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder. British Journal of Psychiatry, 202, 301-306.
• Amsterdam, J.D., Shults, J., Brunswick, D.J., & Hundert, M. (2004). Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression: Low manic switch rate. Bipolar Disorders, 6, 75-81.
• Angst, J., Angst, F., Gerber-Werder, R., & Gamma, A. (2005). Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years’ follow-up. Archives of Suicide Research, 9, 279-300.
• Baastrup, P.C., Poulsen, J.C., Schou, M., Thomsen, K., & Amdisen, A. (1970). Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet, 2, 326-330.
• Baldessarini, R.J., Tondo, L., & Viguera, A.C. (1999). Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disorders, 1, 17-24.
• Berghofer, A., Grof, P., & Müller-Oerlinghausen, B. (2006). Recommendations for the safe use of lithium. In M. Bauer, P. Grof, & B. Müller-Oerlinghausen, Lithium in NeuroPsychiatry (pp 443-464). London: Informa Healthcare.
• Berk, M., Copolov, D.L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., e.a. (2008). N-acetyl cysteine for depressive symptoms in bipolar disorder - A doubleblind randomized placebo-controlled trial. Biological Psychiatry, 64, 468-475.
• Berk, M., Dean, O.M., Cotton, S.M., Gama, C.S., Kapczinski, F., Fernandes, B., e.a. (2012). Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. BMC Medicine, 10, 91.
• Berky, M., Wolf, C., & Kovács, G. (1998). A randomised, double-blind one-year study in 168 patients followed by an open prolongation of one year. European Archives of Psychiatry and Clinical Neurosciences, 248, S119.
• Berwaerts, J., Melkote, R., Nuamah, I., & Lim, P. (2012), A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. Journal of Affective Disorders, 138, 247-258.
• Bobo, W.V., Epstein, R.A., Lynch, A., Patton, T.D., Bossaller, N.A., & Shelton, R.C. (2011). A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder. Clinical Neuropharmacology, 34, 224-233.
• Bowden, C.L., Swann, A.C., Calabrese, J.R., McElroy, S.L., Morris, D., Petty, F., e.a. (1997). Maintenance clinical trials in bipolar disorder: Design implications of the divalproex-lithium-placebo study. Psychopharmacology Bulletin, 33, 693-699.
• Bowden, C.L., Calabrese, J.R., McElroy, S.L., Gyulai L, Wassef, A., Petty, F., e.a. (2000). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archives of General Psychiatry, 57, 481-489.
• Bowden, C.L., Calabrese, J.R., Sachs, G., Yatham, L.N., Asghar, S.A., Hompland, M., e.a. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry, 60, 392-400.
• Bowden, C.L., Collins, M.A., McElroy, S.L., Calabrese, J.R., Swann, A.C., Weisler, R.H., e.a. (2005). Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology, 30, 1932-1939.
• Bowden, C.L., Calabrese, J.R., Ketter, T.A., Sachs, G.S., White, R.L., & Thompson, T.R. (2006). Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. American Journal of Psychiatry, 163, 1199-1201.
• Bowden, C.L., Gundapaneni, B., O’Gorman, C., Pappadopulos, E., Schwartz, J., Kobes, R., e.a. (2010a, May). Treatment outcomes based on disease severity for subjects with bipolar I disorder treated with ziprasidone plus a mood stabilizer [Poster Number: NR4-13]. In: J. Licinio (Chair), 163rd Annual
• Meeting of the American Psychiatric Association. New Orleans, LA: APA. Bowden, C.L., Vieta, E., Ice, K.S., Schwartz, J.H., Wang, P.P., & Versavel, M. (2010b). Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. Journal of Clinical Psychiatry, 71, 130-137.
• Bowden, C.L., Singh, V., Weisler, R., Thompson, P., Chang, X., Quinones, M., e.a. (2012). Lamotrigine vs. lamotrigine plus divalproex in randomized, placebocontrolled maintenance treatment for bipolar depression. Acta Psychiatrica Scandinavica, 126, 342-350.
• Burdick, K.E., Braga, R.J., Nnadi, C.U., Shaya, Y., Stearns, W.H., & Malhotra, A.K. (2012). Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. Journal of Clinical Psychiatry, 73, 103-112.
• Calabrese, J.R., Bowden, C.L., Sachs, G., Yatham, L.N., Behnke, K., Mehtonen, O.P., e.a. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry, 64, 1013-1024.
• Calabrese, J.R., Shelton, M.D., Rapport, D.J., Youngstrom, E.A., Jackson, K., Bilali, S., e.a. (2005). A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. American Journal of Psychiatry, 162, 2152-2161.
• Calabrese, J.R., Suppes, T., Bowden, C.L., Sachs, G.S., Swann, A.C., McElroy, S.L., e.a. (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry, 61, 841-850.
• Caldwell, D.M., Ades, A.E., & Higgins, J.P. (2005). Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ, 331, 897-900.
• Calvert, N.W., Burch, S.P., Fu, A.Z., Reeves, P., & Thompson, T.R. (2006). The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. Journal of Managed Care Pharmacy, 12, 322-330.
• Carlson, B.X., Ketter, T.A., Sun, W., Timko, K., McQuade, R.D., Sanchez, R., e.a. (2012). Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disorders, 14, 41-53.
• Christensen, J., Gronborg, T.K., Sorensen, M.J., Schendel, D., Parner, E.T., Pedersen, L.H., e.a. (2013). Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA, 309, 1696-1703.
• Cipriani, A., Pretty, H., Hawton, K., & Geddes, J.R. (2005). Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. American Journal of Psychiatry, 162, 1805-1819.
• Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P., Churchill, R., e.a. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet, 373, 746-758.
• Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., e.a. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. Lancet, 378, 1306-1315.
• Cipriani, A., Reid, K., Young, A.H., Macritchie, K., & Geddes, J. (2013a). Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database of Systematic Reviews;10:CD003196.
• Cipriani, A., Hawton, K., Stockton, S., & Geddes, J.R. (2013b). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ, 346, f3646.
• Cipriani, A., Barbui, C., Rendell, J., & Geddes, J.R. (2014). Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. Acta Psychiatrica Scandinavica, 129, 328-342.
• Coxhead, N., Silverstone, T., & Cookson, J. (1992). Carbamazepine versus  lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatrica Scandinavica, 85, 114-118.
• Cundall, R.L., Brooks, P.W., & Murray, L.G. (1972). A controlled evaluation of lithium prophylaxis in affective disorders. Psychological Medicine, 2, 308-311.
• Curtis, L. (2013). Unit costs of health and Social care 2013. Canterbury: University of Kent.
• Dubovsky, S.L., & Dubovsky, A.N. (2012). Maintenance treatment of bipolar disorder with ziprasidone in adjunctive use with lithium or valproate. Clinical Medicine Insights: Therapeutics, 4, 1-8.
• Dunner, D.L., Stallone, F., & Fieve, R.R. (1976). Lithium carbonate and affective disorders, V: A double-blind study of prophylaxis of depression in bipolar illness. Archives of General Psychiatry, 33, 117-120.
• Ekman, M., Lindgren, P., Miltenburger, C., Meier, G., Locklear, J.C., & Chatterton, M.L. (2012). Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. PharmacoEconomics, 30, 513-530.
• El-Mallakh, R.S. (2010). A blinded, randomized comparison of immediate-release and extended-release carbamazepine capsules in manic and depressed bipolar subjects. Annals of Clinical Psychiatry, 22, 3-8.
• El-Mallakh, R.S., Salem, M.R., Chopra, A.S., Mickus, G.J., & Penagaluri, P. (2009). Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study. International Clinical Psychopharmacology, 24, 145-149.
• Esparon, J., Kolloori, J., Naylor, G.J., Mcharg, A.M., Smith, A.H.W., & Hopwood, S.E. (1986). Comparison of the Prophylactic Action of Flupentixol with Placebo in Lithium Treated Manic-Depressive Patients. British Journal of Psychiatry, 148, 723-725.
• Fajutrao, L.P. (2009). Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: Results of a markov model analysis. Clinical Therapeutics, 31, 1456-1468.
• Geddes, J.R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G.M. (2004). Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. American Journal of  Psychiatry, 161, 217-222.
• Geddes, J.R., Goodwin, G.M., Rendell, J., Azorin, J.M., Cipriani, A., Ostacher, M.J., e.a. (2010). Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet, 375, 385-395.
• Geddes, J.R., & Miklowitz, D.J. (2013). Treatment of bipolar disorder. Lancet, 381, 1672-1682.
• Gelenberg, A.J., Kane, J.M., Keller, M.B., Lavori, P., Rosenbaum, J.F., Cole, K., e.a. (1989). Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. New England Journal of Medicine, 321, 1489-1493.
• Ghaemi, S.N., Ostacher, M.M., El-Mallakh, R.S., Borrelli, D., Baldassano, C.F., Kelley, M.E., e.a. (2010). Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. Journal of Clinical Psychiatry, 71, 372-380.
• Ghaemi, S.N., Wingo, A.P., Filkowski, M.A., & Baldessarini, R.J. (2008). Longterm antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatrica Scandinavica, 118, 347-356.
• Gijsman, H.J., Geddes, J.R., Rendell, J.M., Nolen, W.A., & Goodwin, G.M. (2004). Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. American Journal of Psychiatry, 161, 1537-15347.
• GlaxoSmithKline (2012a). A clinical evaluation of BW430C (lamotrigine) in bipolar I disorder: Long-term extension study (extension of study SCA104779) [SCA106052]. Available from: http://www.gsk-clinicalstudyregister.com/study/SCA106052#ps [accessed 4 March 2014].
• GlaxoSmithKline (2012b). An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in patients with bipolar I disorder [SCA104779]. Available from: http://www.gsk-clinicalstudyregister. com/study/SCA104779#ps [accessed 4 March 2014].
• Glover, G., Arts, G., & Babu, K.S. (2006). Crisis resolution/home treatment teams and psychiatric admission rates in England. British Journal of Psychiatry, 189, 441-445.
• Goldberg, J.F. (2008). Six-month prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder. Biological Psychiatry, 63, 125-130.
• Greil, W., Haag, M., Huber, D., & Schmidt, S. (1986). Maintenance treatment in affective-disorders - overview and design of a collaborative study. PharmacoPsychiatry, 19, 167-169.
• Greil, W., Kleindienst, N., Erazo, N., & Muller-Oerlinghausen, B. (1998). Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. Journal of Clinical Psychopharmacology, 18, 455-460.
• Greil, W., Ludwig-Mayerhofer, W., Erazo, N., Schochlin, C., Schmidt, S., Engel, R.R., e.a. (1997). Lithium versus carbamazepine in the maintenance  treatment of bipolar disorders--a randomised study. Journal of Affective Disorders, 43, 151-161.
• Greil, W., Ludwig-Mayerhofer, W., Steller, B., Czernik, A., Giedke, H., MullerOerlinghausen, B., e.a. (1993). The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders. Journal of Affective Disorders, 28, 257-265.
• Grunze, H., Vieta, E., Goodwin, G.M., Bowden, C., Licht, R.W., Möller, H.J., e.a.; WFSBP Task Force on Treatment Guidelines for Bipolar disorders. (2013). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World Journal of Biological Psychiatry, 14, 154-219.
• Gyulai, L., Bowden, C.L., McElroy, S.L., Calabrese, J.R., Petty, F., Swann, A.C., e.a. (2003). Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology, 28, 1374-1382.
• Hartong, E.G., Moleman, P., Hoogduin, C.A., Broekman, T.G. & Nolen, W.A.; LitCar Group (2003). Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. Journal of Clinical Psychiatry, 64, 144-151.
• Hayes, J., Prah, P., Nazareth, I., King, M., Walters, K., Petersen, I., e.a. (2011). Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS One, 6, e28725.
• Holmes, L.B., Harvey, E.A., Coull, B.A., Huntington, K.B., Khoshbin, S., Hayes, A.M., e.a. (2001). The teratogenicity of anticonvulsant drugs. New England Journal of Medicine, 344, 1132-1138.
• Jensen, H.V., Plenge, P., Mellerup, E.T., Davidsen, K., Toftegaard, L., Aggernaes, H., e.a. (1995). Lithium prophylaxis of manic-depressive disorder: daily lithium dosing schedule versus every second day. Acta Psychiatrica Scandinavica, 92, 69-74.
• Jensen, H.V., Davidsen, K., Toftegaard, L., Mellerup, E.T., Plenge, P., Aggernaes, H., e.a. (1996a). Double-blind comparison of the side-effect profiles of daily versus alternate-day dosing schedules in lithium maintenance treatment of manic-depressive disorder. Journal of Affective Disorders, 36, 89-93.
• Jensen, H.V., Plenge, P., Stensgaard, A., Mellerup, E.T., Thomsen, C., Aggernaes, H., e.a. (1996b). Twelve-hour brain lithium concentration in lithium maintenance treatment of manic-depressive disorder: daily versus alternate-day dosing schedule. Psychopharmacology (Berl), 124, 275-278.
• Johnson, S., Nolan, F., Pilling, S., Sandor, A., Hoult, J., McKenzie, N., e.a. (2005). Randomised controlled trial of acute mental health care by a crisis resolution team: the north Islington crisis study. BMJ, 331, 599.
• Judd, L., Akiskal, H.S., Schettler, P., Coryell, W., Endicott, J., Maser, J.D., e.a. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry, 60, 261-269.
• Judd, L., Akiskal, H.S., Schettler, P., Endicott, J., Maser, J., Solomon, D.A., e.a. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry, 59, 530-537.
• Judd, L.L., Schettler, P.J., Akiskal, H.S., Coryell, W., Leon, A.C., Maser, J.D., e.a. (2008). Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Archives of General Psychiatry, 65, 386-394.
• Keck, J. (2007). Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo. Journal of Clinical Psychiatry, 68, 1480-1491.
• Keck, P.E. Bowden, C.L., Meinhold, J.M., Gyulai, L., Prihoda, T.J., Baker, J.D., e.a. (2005). Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy. International Journal of Psychiatry in Clinical Practice, 9, 271-277.
• Keck, P.E. Jr., Calabrese, J.R., McQuade, R.D., Carson, W.H., Carlson, B.X., Rollin, L.M., e.a. (2006). A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. Journal of Clinical Psychiatry, 67, 626-637.
• Keller, M.B., Lavori, P.W., Kane, J.M., Gelenberg, A.J., Rosenbaum, J.F., Walzer, E.A., e.a. (1992). Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Archives of General Psychiatry, 49, 371-376.
• Kemp, D.E. (2012). Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profiles. European Neuropsychopharmacology, 22, 123-131.
• Kemp, D.E., De Hert, M., Rahman, Z., Fyans, P., Eudicone, J.M., Marler, S.V., e.a. (2013). Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine. Journal of Affective Disorders, 148, 84-91.
• Kerr, M., Bray, B., Medcalf, J., O’Donoghue, D.J., & Matthews, B. (2012). Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrology, Dialysis, Transplantation, 27(Suppl 3), iii73-iii80.
• Kessing, L.V., Hansen, H.V., Hvenegaard, A., Christensen, E.M., Dam, H., Gluud, C., e.a. (2013). Treatment in a specialised out-patient mood disorder clinic V standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. British Journal of Psychiatry, 202, 212-219.
• Kleindienst, N., & Greil, W. (2000). Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology, 42(Suppl 1), 2-10.
• Kleindienst, N., & Greil, W. (2004). Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? Journal of Clinical Psychiatry, 65, 966-974.
• Kripalani, M., Shawcross, J., Reilly, J., & Main, J. (2009). Lithium and chronic kidney disease. BMJ, 339, b2452.
• Langosch, J.M., Drieling, T., Biedermann, N.C., Born, C., Sasse, J., Bauer, H., e.a. (2008). Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. Journal of Clinical Psychopharmacology, 28, 555-560.
• Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., e.a. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382, 951-962.
• Licht, R.W., Nielsen, J.N., Gram, L.F., Vestergaard, P., & Bendz, H. (2010). Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders, 12, 483-493.
• Loo, C., Katalinic, N., Mitchell, P.B., & Greenberg, B. (2011). Physical treatments for bipolar disorder: a review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques. Journal of Affective Disorders, 132, 1-13.
• Macfadden, W., Alphs, L., Haskins, J.T., Turner, N., Turkoz, I., Bossie, C., e.a. (2009). A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disorders, 11, 827-839.
• Marcus, R. (2011). Aripiprazole improved time to any mood episode when added to mood stabilizer. Psychiatric Annals, 41, 353.
• Marcus, R., Khan, A., Rollin, L., Morris, B., Timko, K., Carson, W., e.a. (2011). Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disorders, 13, 133-144.
• McCrone, P., Johnson, S., Nolan, F., Pilling, S., Sandor, A., Hoult, J., e.a. (2009). Economic evaluation of a crisis resolution service: a randomised controlled trial. Epidemiologia e Psichiatria Sociale, 18, 54-58.
• McKendrick, J.C. (2007). Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. Journal of Psychopharmacology, 21, 588-596.
• McKnight, R.F., Adida, M., Budge, K., Stockton, S., Goodwin, G.M., & Geddes, J.R. (2012). Lithium toxicity profile: a systematic review and meta-analysis. Lancet, 379, 721-728.
• Mendlewicz, J., Fieve, R.R., & Stallone, F. (1973). Relationship between the effectiveness of lithium therapy and family history. American Journal of Psychiatry, 130, 1011-1013.
• Mendlewicz, J., & Stallone, F. (1975). Genetic factors and lithium response in manic-depressive illness. Modern Problems of Pharmacopsychiatry, 10, 23-29.
• Minnai, G.P., Salis, P.G., Oppo, R., Loche, A.P., Scano, F., & Tondo, L. (2011). Effectiveness of maintenance electroconvulsive therapy in rapid-cycling bipolar disorder. Journal of ECT, 27, 123-126.
• Miura, T., Noma, H., Furukawa, T.A., Mitsuyasu, H., Tanaka, S., Stockton, S., e.a. (2014). Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry, 1, 351-359.
• Morrow, J., Russell, A., Guthrie, E., Parsons, L., Robertson, I., Waddell, R., e.a. (2006). Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Psychiatry, 77, 193-198.
• Murphy, B.L., Stoll, A.L., Harris, P.Q., Ravichandran, C., Babb, S.M., Carlezon, W.A. Jr., e.a. (2012). Omega-3 fatty acid treatment, with or without  cytidine, fails to show therapeutic properties in bipolar disorder: a doubleblind, randomized add-on clinical trial. Journal of Clinical Psychopharmacology, 32, 699-703.
• NHS (2012). Hospital episode statistics: Admitted patient care 2011-12: Summary report 2011-12. London: National Health Service, The Information Centre.
• NHS Business Services Authority PPD (2014). Electronic Drug Tariff for England and Wales, February 2014. Redditch, UK: NHS.
• NHS DoH (2013). NHS Reference Costs 2012-13. London: NHS, Department of Health.
• NICE (2014). Psychosis and schizophrenia in adults [CG178]. London: National Institute for Health and Care Excellence.
• NICE/NCCMH (2006). Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Leicester and London: The British Psycholgical Society and The Royal College of Psychiatrists.
• NICE/NCCMH (2014). Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. London: National Institute for Health and Care Excellence.
• Nielsen, J., Kane, J.M., & Correll, C.U. (2012). Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirrorimage study. Bipolar Disorders, 14, 863-869.
• Nolen, W.A., & Weisler, R.H. (2013). The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: A post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disorders, 15, 100-109.
• Norris, E.R., Karen, B., Correll, J.R., Zemanek, K.J., Lerman, J., Primelo, R.A., e.a. (2013). A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. Journal of Affective Disorders, 144, 141-147.
• O’Brien, M.D., & Gilmour-White, S.K. (2005). Management of epilepsy in women. Postgraduate Medical Journal, 81, 278-285.
• Okuma, T., Inanaga, K., & Otsuki S. (1981). A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology, 73, 95-96.
• Omtzigt, J.G., Nau, H., Los, F.J., Pijpers, L., & Lindhout, D. (1992). The disposition of valproate and its metabolites in the late first trimester and early second trimester of pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, co-medication, and the presence of spina bifida. European Journal of Clinical Pharmacology, 43, 381-388.
• Perlis, R.H., Sachs, G.S., Lafer, B., Otto, M.W., Faraone, S.V., Kane, J.M., e.a. (2002). Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. American Journal of Psychiatry, 159, 1155-1159.
• Prien, R.F., Caffey, E.M. Jr., & Klett, C.J. (1973a). Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Archives of General Psychiatry, 28, 337-341.
• Prien, R.F., Klett, C.J., & Caffey, E.M. Jr. (1973b). Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Archives of General Psychiatry, 29, 420-425.
• Prien, R.F., Klett, C.J., & Caffey, E.M. Jr. (1974). Lithium prophylaxis in recurrent affective illness. American Journal of Psychiatry, 131, 198-203.
• Prien, R.F., Kupfer, D.J., Mansky, P.A., Small, J.G., Tuason, V.B., Voss, C.B., e.a. (1984). Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Archives of General Psychiatry, 41, 1096-1104.
• Quiroz, J.A., Yatham, L.N., Palumbo, J.M., Karcher, K., Kushner, S., & Kusumakar, V. (2010). Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biological Psychiatry, 68, 156-162.
• Quitkin, F., Rifkin, A., & Kane, J. (1979). The prophylactic effect of lithium and imipramine in bipolar II and unipolar patients: a preliminary report [proceedings]. Psychopharmacology Bulletin, 15, 35-39.
• Quitkin, F.M., Kane, J., Rifkin, A., Ramos-Lorenzi, J.R., & Nayak, D.V. (1981). Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. A double-blind study. Archives of General Psychiatry, 38, 902-907.
• Rahman, Z. (2011). Effect of aripiprazole in combination with lamotrigine in the long-term maintenance of patients with bipolar I disorder [Poster Number: CN138-392]. Bipolar Disorders, 13(Suppl 1), 79.
• Revicki, D.A., Hirschfeld, R.M., Ahearn, E.P., Weisler, R.H., Palmer, C., & Keck, P.E. Jr. (2005). Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial. Journal of Affective Disorders, 86, 183-193.
• Sajatovic, M., Gyulai, L., Calabrese, J.R., Thompson, T.R., Wilson, B.G., White, R., e.a. (2005). Maintenance treatment outcomes in older patients with bipolar I disorder. American Journal of Geriatric Psychiatry, 13, 305-311.
• Severus, E., Taylor, M.J., Sauer, C., Pfennig, A., Ritter, P., Bauer, M., & Geddes, J.R. (2014). Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. International Journal of Bipolar  Disorders, 2, 15.
• Shapiro, D.R., Quitkin, F.M., & Fleiss, J.L. (1989). Response to maintenance therapy in bipolar illness: Effect of index episode. Archives of General  Psychiatry, 46, 401-405.
• Sidor, M.M., & MacQueen, G.M. (2012). An update on antidepressant use in bipolar depression. Current Psychiatry Reports, 14, 696-704.
• Soares-Weiser, K.V., Bravo Vergel, Y., Beynon, S., Dunn, G., Barbieri, M., Duffy, S., e.a. (2007). A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technology Assessment, 11, iii-iv, ix-206.
• Solomon, D.A., Ristow, W.R., Keller, M.B., Kane, J.M., Gelenberg, A.J., Rosenbaum, J.F., e.a. (1996). Serum lithium levels and psychosocial function in patients with bipolar I disorder. American Journal of Psychiatry, 153, 13011307.
• Solomon, D.A., Ryan, C.E., Keitner, G.I., Miller, I.W., Shea, M.T., Kazim, A., e.a. (1997). A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. Journal of Clinical Psychiatry, 58, 95-99.
• Stallone, F., Shelley, E., Mendlewicz, J., & Fieve, R.R. (1973). The use of lithium in affective disorders, 3: A double-blind study of prophylaxis in bipolar illness. American Journal of Psychiatry, 130, 1006-1010.
• Stoll, A.L., Severus, W.E., Freeman, M.P., Rueter, S., Zboyan, H.A., Diamond, E., e.a. (1999). Omega 3 fatty acids in bipolar disorder: a preliminary doubleblind, placebo-controlled trial. Archives of General Psychiatry, 56, 407-412.
• Suppes, T. (2009). Maintenance treatment with quetiapine added to either lithium or divalproex in bipolar I disorder. Journal of Cancer Education Conference.
• Suppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., & Rush, A.J. (1999). Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. American Journal of Psychiatry, 156, 1164-1169.
• Suppes, T., Vieta, E., Liu, S., Brecher, M., & Paulsson, B. (2009). Trial I, maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). American Journal of Psychiatry, 166, 476-488.
• Thies-Flechtner, K., Muller-Oerlinghausen, B., Seibert, W., Walther, A., & Greil, W. (1996). Effect of prophylactic treatment on suicide risk in patients with major affective disorders: Data from a randomized prospective trial. PharmacoPsychiatry, 29, 103-107.
• Tohen, M., Chengappa, K.N., Suppes, T., Zarate, C.A. Jr., Calabrese, J.R., Bowden, C.L., e.a. (2002). Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Archives of General Psychiatry, 59, 62-69.
• Tohen, M., Chengappa, K.N., Suppes, T., Baker, R.W., Zarate, C.A., Bowden, C.L., e.a. (2004). Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. British Journal of Psychiatry, 184, 337-345.
• Tohen, M., Greil, W., Calabrese, J.R., Sachs, G.S., Yatham, L.N., Oerlinghausen, B.M., e.a. (2005). Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry, 162, 1281-1290.
• Tohen, M., Calabrese, J.R., Sachs, G.S., Banov, M.D., Detke, H.C., Risser, R., e.a. (2006). Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. American Journal of Psychiatry, 163, 247-256.
• Tohen, M., Wang, W.V., Leboyer, M., & Jen, K.Y. (2012). Variables as mediators or moderators in predicting relapse to any type of mood episode in a bipolar maintenance study. Journal of Clinical Psychiatry, 73, e913-e17.
• Vieta, E., Manuel Goikolea, J., Martínez-Arán, A., Comes, M., Verger, K., Masramon, X., e.a. (2006). A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. Journal of Clinical Psychiatry, 67, 473-477.
• Vieta, E., Cruz, N., Garcia-Campayo, J., De Arce, R., Manuel Crespo, J., Valles, V., e.a. (2008a). A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. International Journal of Neuropsychopharmacology, 11, 445-452.
• Vieta, E., Suppes, T., Eggens, I., Persson, I., Paulsson, B., & Brecher, M. (2008b). Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). Journal of Affective Disorders, 109, 251-263.
• Vieta, E., Montgomery, S., Sulaiman, A.H., Cordoba, R., Huberlant, B., Martinez, L., e.a. (2012a). A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. European Neuropsychopharmacology, 22, 825-835.
• Vieta, E., Suppes, T., Ekholm, B., Udd, M., & Gustafsson, U. (2012b). Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. Journal of Affective Disorders, 142, 36-44.
• Vries, C. de, Bergen, A. van, Regeer, E.J., Benthem, E., Kupka, R.W., & Boks, M.P. (2013). The effectiveness of restarted lithium treatment after discontinuation: reviewing the evidence for discontinuation-induced refractoriness. Bipolar Disorders, 15, 645-649.
• Weisler, R.H. (2009). Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. Bipolar Disorders, 11(Suppl 1), 89.
• Weisler, R.H., Nolen, W.A., Neijber, A., Hellqvist, A., & Paulsson, B. (2011). Trial 144 Study I. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). Journal of Clinical Psychiatry, 72, 1452-1464.
• Werneke, U., Ott, M., Renberg, E.S., Taylor, D., & Stegmayr, B. (2012). A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiatrica Scandinavica, 126, 186-197.
• Wolf, C., Berky, M., & Kovacs, G. (1997). Carbamazepine versus lithium in the prophylaxis of bipolar affective disorders: a randomised, double-blind 1-year study in 168 patients. In 10th European College of Neuropsychopharmacology Congress, 13-17 September 1997. Vienna, Austria.
• Woo, Y.S., Bahk, W.M., Chung, M.Y., Kim, D.H., Yoon, B.H., Lee, J.H., e.a. (2011). Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, doubleblind maintenance trial. Human Psychopharmacology, 26, 543-553.
• Woodward, T.C.T. (2009). Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder. Journal of Medical Economics, 12, 259-268.
• Woodward, T.C.T. (2010). Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. PharmacoEconomics, 28, 751-764.
• Yatham, L.N., Fountoulakis, K.N., Rahman, Z., Ammerman, D., Fyans, P., Marler, S.V., e.a. (2013a). Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. Journal of Affective Disorders, 147, 365-372.
• Yatham, L.N., Kennedy, S.H., Parikh, S.V., Schaffer, A., Beaulieu, S., Alda, M., e.a. (2013b). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 15, 1-44.
• Young, A.H., McElroy, S.L., Olausson, B., & Paulsson, B. (2012). A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World Journal of Biological Psychiatry, 15, 96-112.
• Zarate, C.A. Jr., & Tohen, M. (2014). Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. American Journal of Psychiatry, 161, 169-171.